JAMA Oncology:卵巢癌风险降低23%!神药阿司匹林再添3个喜讯!

2018-10-08 Paris,Zoe 转化医学网

为了研究阿司匹林在癌症治疗中的作用,Elwood及其同事分析了71项研究,汇集了超过120,000名肿瘤患者,在这些患者接受常规肿瘤的同时,也服用相应剂量的阿司匹林。研究人员将这些数据与大约400,000没有服用阿司匹林的肿瘤患者的数据进行了比较。在这份研究中囊括了29项结直肠癌研究、14项乳腺癌研究和16项前列腺癌研究。结果表明,阿司匹林或将结肠癌死亡风险降低25%,乳腺癌死亡风险降低20%,前

阿司匹林的药用价值一直以来都是人们关注焦点,此前有证据表明服用小剂量阿司匹林可作为心脏病、中风和癌症的预防药物,甚至出现在健康指南中,还有证据表明阿司匹林可治疗阿兹海默症!之前《PLOS ONE》刊更是发了一项系统性综述新进展,研究人员对既往71项临床研究进行分析,发现定期服用阿司匹林可以作为癌症的辅助治疗药物,并且发挥重要作用。近日,神刊《JAMA oncology》更是发表了数篇文章来报道关于神药阿司匹林与肝细胞癌、卵巢癌等相关性的研究,其中一篇还占据了该刊的头条,其成果可谓是硕果累累。

阿司匹林与直肠癌乳腺癌和前列腺癌

为了研究阿司匹林在癌症治疗中的作用,Elwood及其同事分析了71项研究,汇集了超过120,000名肿瘤患者,在这些患者接受常规肿瘤的同时,也服用相应剂量的阿司匹林。研究人员将这些数据与大约400,000没有服用阿司匹林的肿瘤患者的数据进行了比较。在这份研究中囊括了29项直肠癌研究、14项乳腺癌研究和16项前列腺癌研究。结果表明,阿司匹林或将结肠癌死亡风险降低25%,乳腺癌死亡风险降低20%,前列腺癌死亡风险降低15%。

阿司匹林与肝细胞癌

由麻省总医院(MGH)调查人员领导的一项研究结果支持先前研究的证据,即定期服用阿司匹林可以降低原发性肝癌——也称为肝细胞癌(HCC)的风险。他们的报告分析了两项长期流行病学研究的数据:常规服用阿司匹林——每周服用两片或两片以上,持续5年或更长时间——可显着降低肝癌的风险。

该研究小组审查了作为护士健康研究和保健专业人员后续研究的一部分而收集的30多年的数据,这些数据汇编了自1980年代以来超过17万名参与者的综合健康数据。在分析数据的逾13.33万名参与者中——超过45800名女性和87500名男性——常规服用阿司匹林,即每周服用两片或两片以上的标准剂量药片,结果导致患HCC的相对风险降低了49%。在服用阿司匹林五年或更长时间的人中,相对风险降低了59%。他们还发现,随着阿司匹林使用时间的延长,这种风险也会降低得更多。

阿司匹林与卵巢癌

哈佛大学公共卫生学院领导的一项新研究显示,与那些没有定期服用阿司匹林的女性相比,近期定期服用低剂量阿司匹林(100毫克或更少)的女性患卵巢癌的风险降低了23%。研究还发现长期大量使用非阿司匹林类非甾体抗炎药可能会增加患卵巢癌的风险。

在这项研究中,哈佛禅学研究人员与来自波士顿布里格姆妇女医院和坦帕莫菲特癌症中心的同事一起分析了205498名参加护士健康研究和护士健康研究二的妇女的数据。其中1054人患上了卵巢癌。研究人员研究了妇女服用标准剂量阿司匹林、小剂量阿司匹林、非阿司匹林类非甾体抗炎药和对乙酰氨基酚的情况,以及使用的药片数量、频率、时间和持续时间等方面的信息。

结果表明,近期使用低剂量阿司匹林与降低卵巢癌风险相关,而使用标准剂量阿司匹林(325毫克)则无相关性。然而,研究人员并没有观察到低剂量阿司匹林使用时间越长,卵巢癌的风险就越低。该分析还表明,如果连续多年每周至少服用10片非阿司匹林非甾体抗炎药,如布洛芬和萘普生,可能会增加患卵巢癌的风险。

这样看来,阿司匹林对于肿瘤的影响显示出的积极效果更加显着。而以上研究结果都旨在强调研究阿司匹林的使用和癌症风险之间的关系时必须考虑阿司匹林的剂量这一问题。当然,在患者和医生之间就服用低剂量阿司匹林的风险和益处进行持续对话也相当重要。

原始出处:Barnard ME, Poole EM, Curhan GC, et al. Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses' Health Studies. JAMA Oncol. 2018 Oct 4.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1865560, encodeId=37c8186556022, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Nov 21 15:35:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061785, encodeId=52622061e85ee, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Jan 13 09:35:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820677, encodeId=436218206e74b, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Thu Jan 10 17:35:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674458, encodeId=a3ac16e445847, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Mar 25 20:35:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348471, encodeId=a71b3484e17b, content=了解一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Oct 08 10:07:55 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348470, encodeId=3d173484e055, content=厉害了,阿司匹林, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Oct 08 10:06:21 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348442, encodeId=8a9d3484425b, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Oct 08 07:09:05 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348438, encodeId=af05348438cc, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Mon Oct 08 06:49:31 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
    2018-11-21 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1865560, encodeId=37c8186556022, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Nov 21 15:35:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061785, encodeId=52622061e85ee, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Jan 13 09:35:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820677, encodeId=436218206e74b, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Thu Jan 10 17:35:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674458, encodeId=a3ac16e445847, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Mar 25 20:35:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348471, encodeId=a71b3484e17b, content=了解一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Oct 08 10:07:55 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348470, encodeId=3d173484e055, content=厉害了,阿司匹林, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Oct 08 10:06:21 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348442, encodeId=8a9d3484425b, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Oct 08 07:09:05 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348438, encodeId=af05348438cc, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Mon Oct 08 06:49:31 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
    2019-01-13 sjq027
  3. [GetPortalCommentsPageByObjectIdResponse(id=1865560, encodeId=37c8186556022, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Nov 21 15:35:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061785, encodeId=52622061e85ee, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Jan 13 09:35:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820677, encodeId=436218206e74b, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Thu Jan 10 17:35:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674458, encodeId=a3ac16e445847, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Mar 25 20:35:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348471, encodeId=a71b3484e17b, content=了解一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Oct 08 10:07:55 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348470, encodeId=3d173484e055, content=厉害了,阿司匹林, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Oct 08 10:06:21 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348442, encodeId=8a9d3484425b, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Oct 08 07:09:05 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348438, encodeId=af05348438cc, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Mon Oct 08 06:49:31 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1865560, encodeId=37c8186556022, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Nov 21 15:35:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061785, encodeId=52622061e85ee, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Jan 13 09:35:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820677, encodeId=436218206e74b, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Thu Jan 10 17:35:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674458, encodeId=a3ac16e445847, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Mar 25 20:35:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348471, encodeId=a71b3484e17b, content=了解一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Oct 08 10:07:55 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348470, encodeId=3d173484e055, content=厉害了,阿司匹林, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Oct 08 10:06:21 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348442, encodeId=8a9d3484425b, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Oct 08 07:09:05 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348438, encodeId=af05348438cc, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Mon Oct 08 06:49:31 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1865560, encodeId=37c8186556022, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Nov 21 15:35:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061785, encodeId=52622061e85ee, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Jan 13 09:35:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820677, encodeId=436218206e74b, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Thu Jan 10 17:35:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674458, encodeId=a3ac16e445847, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Mar 25 20:35:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348471, encodeId=a71b3484e17b, content=了解一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Oct 08 10:07:55 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348470, encodeId=3d173484e055, content=厉害了,阿司匹林, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Oct 08 10:06:21 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348442, encodeId=8a9d3484425b, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Oct 08 07:09:05 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348438, encodeId=af05348438cc, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Mon Oct 08 06:49:31 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
    2018-10-08 kafei

    了解一下谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1865560, encodeId=37c8186556022, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Nov 21 15:35:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061785, encodeId=52622061e85ee, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Jan 13 09:35:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820677, encodeId=436218206e74b, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Thu Jan 10 17:35:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674458, encodeId=a3ac16e445847, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Mar 25 20:35:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348471, encodeId=a71b3484e17b, content=了解一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Oct 08 10:07:55 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348470, encodeId=3d173484e055, content=厉害了,阿司匹林, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Oct 08 10:06:21 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348442, encodeId=8a9d3484425b, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Oct 08 07:09:05 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348438, encodeId=af05348438cc, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Mon Oct 08 06:49:31 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
    2018-10-08 cqykthl

    厉害了,阿司匹林

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1865560, encodeId=37c8186556022, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Nov 21 15:35:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061785, encodeId=52622061e85ee, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Jan 13 09:35:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820677, encodeId=436218206e74b, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Thu Jan 10 17:35:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674458, encodeId=a3ac16e445847, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Mar 25 20:35:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348471, encodeId=a71b3484e17b, content=了解一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Oct 08 10:07:55 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348470, encodeId=3d173484e055, content=厉害了,阿司匹林, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Oct 08 10:06:21 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348442, encodeId=8a9d3484425b, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Oct 08 07:09:05 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348438, encodeId=af05348438cc, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Mon Oct 08 06:49:31 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
    2018-10-08 明月清辉

    谢谢分享,学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1865560, encodeId=37c8186556022, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed Nov 21 15:35:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061785, encodeId=52622061e85ee, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Jan 13 09:35:00 CST 2019, time=2019-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820677, encodeId=436218206e74b, content=<a href='/topic/show?id=0c6a1009105e' target=_blank style='color:#2F92EE;'>#风险降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100910, encryptionId=0c6a1009105e, topicName=风险降低)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd18451, createdName=xre2008, createdTime=Thu Jan 10 17:35:00 CST 2019, time=2019-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674458, encodeId=a3ac16e445847, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Mar 25 20:35:00 CST 2019, time=2019-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348471, encodeId=a71b3484e17b, content=了解一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Oct 08 10:07:55 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348470, encodeId=3d173484e055, content=厉害了,阿司匹林, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Oct 08 10:06:21 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348442, encodeId=8a9d3484425b, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6Nx0VGA4QMDzOP8oAgnV4h51EjSfehJ9QxyiaSmw8PB56BhY8KXFSxHCibXrzcy4abrzSibXQPxJ9kzrLcJyhhB8a/0, createdBy=1d3b1672603, createdName=明月清辉, createdTime=Mon Oct 08 07:09:05 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=348438, encodeId=af05348438cc, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRkia1DP5MpwEgtXo1XhXA11xD6MWKxunAZFXKSNic0fWHUQx83oNHPlRMxxIctM83QKeCLkJpMibibiaC/0, createdBy=7e581734408, createdName=深海的鱼, createdTime=Mon Oct 08 06:49:31 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
    2018-10-08 深海的鱼

    学习学习学习

    0

相关资讯

JAMA Network Open:BRCA基因检测应该面向所有女性

遗传性易感基因如BRCA1和BRCA2(BRCA1/2)基因发生突变,会导致很高的乳腺癌和卵巢癌患病风险。然而,最新一项研究表明,目前鉴别BRCA1/2变异携带者的方法可能不足以作为筛选工具,因为有超过80%的人并不知道自己是乳腺癌、卵巢癌、前列腺癌和胰腺癌风险基因携带者。

2018 KSOG立场声明:双侧输卵管切除术降低平均风险女性卵巢癌/输卵管癌/腹膜癌风险

基于当前关于双侧输卵管切除术针对女性卵巢癌/输卵管癌/腹膜癌风险的预防作用的理解,KSGO联合多家韩国医学专业学会组织达成了相关共识。

聚乙二醇化脂质体阿霉素治疗卵巢癌的中国专家共识(2018年)

卵巢癌的治疗一直是妇科肿瘤面临的最艰巨的挑战,理想的细胞减灭术是治疗的基石,以铂类为主的联合化疗方案是卵巢癌化疗的主要方案,但晚期患者即使经过上述治疗获得完全缓解,仍有70% ~80%出现复发。复发性卵巢癌的治疗原则以减轻患者痛苦,提高生活质量,尽可能延长患者生存为目的。

2018 CSCO:尼拉帕利NOVA研究:证据级别高,人群覆盖全面,卵巢癌治疗新希望

卵巢癌是妇科肿瘤中死亡率最高的恶性肿瘤,其治疗一直是临床难点。近年来,聚腺苷酸二磷酸核糖聚合酶(PARP)抑制剂的维持治疗给卵巢癌治疗带来了新曙光。其中,尼拉帕利III期临床试验(NOVA研究)的成功使其成为全球第一个获批用于铂敏感复发卵巢癌患者的维持治疗、而无论BRCA是否突变的PARP抑制剂。

ANN ONCOL:Vistusertib联合紫杉醇治疗高级别浆液性卵巢癌及鳞状非小细胞肺癌

之前的研究表明p-S6K水平升高与卵巢癌化疗耐药有关。有学者认为在接受紫杉醇的患者中使用双效m-TORC1 / 2抑制剂抑制p-S6K信号传导可以改善这些患者的预后。ANN ONCOL近期发表了一篇文章研究这一问题。

CLIN CANCER RES:顺铂耐药的卵巢癌中存在有丝分裂退出异常

顺铂获得性耐药是成功治疗各种癌症的主要障碍。了解顺铂耐药肿瘤细胞特有的有丝分裂机制可为开发靶向有丝分裂的新型疗法提供基础。CLIN CANCER RES近期发表了一篇文章研究这一问题。